Interaction of Curcumin with One Subunit of Monoamine Oxidase-B in Comparison with Safinamide: An In Silico Study

Curcumin is a plant derivative with biological effects, including potential for the treatment of Parkinson’s disease (PD). It is known that monoamine oxidase B (MAO-B) is involved in PD due to its role in the degradation of various neurotransmitters like dopamine, the main declined factor in PD. Since MAO-B inhibitors (e.g. safinamide) are used as the support for the treatment of PD, we planned to evaluate the in silico interaction of curcumin with one subunit of the MAO-B enzyme in comparison with safinamide. The crystal structure of human MAO-B (PDB entry code 3PO7) was selected from the Protein Data Bank (https://www.rcsb.org). The molecular structures of curcumin (CID: 969516) and safinamide (CID: 131682) were obtained from PubChem (https://pubchem.ncbi.nlm.nih.gov). Chimera 1.8, AutoDock Tools-1.5.6 software and AutoDock4 software were used for this in silico study. The results revealed that the binding energies (ΔG)s of the conformations of curcumin and safinamide, showing the best down ΔG, were -11.15 kcal/mol and -11.09 kcal/mol, respectively. Moreover, the inhibition constants (Ki)s of both ligands were near quantities. Hence, it may suggest that curcumin and safinamide form nearly similar stability with the subunit of the MAO-B enzyme. More experimental studies may reveal the similarity of curcumin with safinamide about the inhibitory effect on MAO-B.

[1]  M. Cruz.  Xadago (Safinamide): A Monoamine Oxidase B Inhibitor for the Adjunct Treatment of Motor Symptoms in Parkinson's Disease. , 2017, P & T : a peer-reviewed journal for formulary management.

[2]  Y. Pang,et al.  On the use of the experimentally determined enzyme inhibition constant as a measure of absolute binding affinity , 2017, bioRxiv.

[3]  R. Ramsay.  Molecular aspects of monoamine oxidase B , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[4]  Yuan-Ling Xia,et al.  Insights into Protein–Ligand Interactions: Mechanisms, Models, and Methods , 2016, International journal of molecular sciences.

[5]  B. Mathew,et al.  Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors: Synthesis, biochemistry and molecular docking studies. , 2015, Bioorganic chemistry.

[6]  Xin Wang,et al.  Plant-derived neuroprotective agents in Parkinson's disease. , 2015, American journal of translational research.

[7]  P. Lei,et al.  Neuroprotection of MAO-B inhibitor and dopamine agonist in Parkinson disease. , 2015, International journal of clinical and experimental medicine.

[8]  S. Shakil,et al.  A simple click by click protocol to perform docking: AutoDock 4.2 made easy for non-bioinformaticians , 2013, EXCLI journal.

[9]  Andrea Mattevi,et al.  Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs. , 2012, ACS medicinal chemistry letters.

[10]  P. F. Fitzpatrick,et al.  Structures and mechanism of the monoamine oxidase family , 2011, Biomolecular concepts.

[11]  A. Mattevi,et al.  Interactions of monoamine oxidases with the antiepileptic drug zonisamide: specificity of inhibition and structure of the human monoamine oxidase B complex. , 2011, Journal of medicinal chemistry.

[12]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[13]  M. Sabesan,et al.  Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson’s disease induced by MPTP neurodegeneration in mice , 2008, Inflammopharmacology.

[14]  Andrea Mattevi,et al.  Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Srikanth.  Discovery of Novel Monoamine Oxidase-B Inhibitors by Molecular Docking Approach for Alzheimer ’ s and Parkinson ’ s Disease Treatment , 2016 .

[16]  S. Bengmark,et al.  Plant-derived health: the effects of turmeric and curcuminoids. , 2009, Nutricion hospitalaria.